Exact Sciences - EXAS Stock Forecast, Price & News

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EXAS shares.
View EXAS analyst ratings or view top-rated stocks.

13 analysts have issued 12-month price objectives for Exact Sciences' stock. Their EXAS share price forecasts range from $55.00 to $92.00. On average, they anticipate the company's share price to reach $74.14 in the next twelve months. This suggests a possible upside of 11.9% from the stock's current price.
View analysts price targets for EXAS or view top-rated stocks among Wall Street analysts.

Exact Sciences' stock was trading at $49.51 at the start of the year. Since then, EXAS stock has increased by 33.8% and is now trading at $66.26.
View the best growth stocks for 2023 here.

Exact Sciences saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 12,380,000 shares, a decline of 5.3% from the February 28th total of 13,070,000 shares. Based on an average daily volume of 2,510,000 shares, the short-interest ratio is currently 4.9 days.
View Exact Sciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 25th 2023.
View our EXAS earnings forecast.

Exact Sciences Co. (NASDAQ:EXAS) posted its earnings results on Tuesday, February, 21st. The medical research company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.90) by $0.18. The medical research company earned $553 million during the quarter, compared to the consensus estimate of $525.61 million. Exact Sciences had a negative net margin of 29.92% and a negative trailing twelve-month return on equity of 19.76%. The company's revenue for the quarter was up 16.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.28) EPS.

ETFs with the largest weight of Exact Sciences (NASDAQ:EXAS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), ARK Innovation ETF (ARKK), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), First Trust Indxx Medical Devices ETF (MDEV), First Trust NYSE Arca Biotechnology Index Fund (FBT), Principal Healthcare Innovators ETF (BTEC), VanEck Biotech ETF (BBH) and First Trust Health Care AlphaDEX Fund (FXH).

Exact Sciences updated its FY 2023 earnings guidance on Tuesday, February, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.27 billion-$2.31 billion, compared to the consensus revenue estimate of $2.29 billion.

328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Block (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV).

Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."

Exact Sciences' stock is owned by a number of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (9.03%), Sumitomo Mitsui Trust Holdings Inc. (3.02%), Price T Rowe Associates Inc. MD (2.81%), Baillie Gifford & Co. (2.77%), Nikko Asset Management Americas Inc. (2.74%) and T. Rowe Price Investment Management Inc. (1.65%). Insiders that own company stock include Canada Pension Plan Investment, D Scott Coward, Everett Cunningham, Graham Peter Lidgard, Jacob A Orville, Jacob A Orville, James Edward Doyle, James Herriott, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Kevin T Conroy, Mark Stenhouse, Sarah Condella and Torsten Hoof.
View institutional ownership trends.

Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EXAS stock can currently be purchased for approximately $66.26.

Exact Sciences (NASDAQ:EXAS) has a market capitalization of $11.81 billion and generates $2.08 billion in revenue each year. The medical research company earns $-623,510,000.00 in net income (profit) each year or ($3.54) on an earnings per share basis.

The company employs 6,400 workers across the globe.

Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The official website for the company is www.exactsciences.com. The medical research company can be reached via phone at (608) 284-5700, via email at meganjones@exactsciences.com, or via fax at 608-284-5701.